CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW
Cardio Diagnostics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.64−0.05 (-2.96%)
Close on Oct 19, 2026
- Market cap
- $4.85M
- P/E (TTM)
- –
- Dividend yield
- –
Cardio Diagnostics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Market Cap | $4.85M | $166.30M |
| Enterprise Value | $4.85M | $88.19M |
| PS Ratio | 327.39 | 3.65 |
| PB Ratio | 0.65 | 2.03 |
| P/TBV Ratio | 0.65 | 2.29 |
Enterprise value
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| EV / Sales | 327.39 | 2.51 |
Income (trailing twelve months)
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Revenue | $14.83K | $58.34M |
| Operating Income | -$6.48M | -$21.40M |
| Pretax Income | -$6.50M | -$14.34M |
| Net Income | -$6.50M | -$22.46M |
| EBITDA | -$6.48M | -$16.91M |
| EPS (Diluted) | -$3.71 | -$0.83 |
Margins
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Operating Margin | -43737.5% | -44.0% |
| Pretax Margin | -43832.5% | -13.3% |
| Profit Margin | -43832.5% | -40.2% |
| EBITDA Margin | -43737.5% | -30.2% |
| FCF Margin | -39893.1% | -9.27% |
Returns
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -87.5% | -53.2% |
| Return on Assets (ROA) | -82.0% | -40.9% |
| Return on Invested Capital (ROIC) | -69.0% | -32.4% |
| Return on Capital Employed (ROCE) | -85.7% | -38.1% |
Growth
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -57.5% | 5.96% |
| Revenue Growth (3Y CAGR) | 149.9% | 2.25% |
Balance sheet
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $0 | $61.43M |
| Net Cash (Debt) | $0 | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $7.43M | $49.09M |
| Book Value Per Share | $2.51 | $1.37 |
| Tangible Book Value | $7.43M | $23.52M |
| Working Capital | $5.80M | $76.81M |
Financial position
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Current Ratio | 17.15 | 3.34 |
| Quick Ratio | 0.01 | 2.44 |
| Interest Coverage | -438.08 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.73M | -$12.35M |
| Capital Expenditures | -$187.32K | -$1.08M |
| Free Cash Flow | -$5.91M | -$20.22M |
| FCF Per Share | -$2.00 | -$0.42 |
Efficiency
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $2.12K | $404.87K |
| Profits Per Employee | -$928.31K | -$703.34K |
| Employee Count | 7 | 74 |
Dividends and yields
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Earnings Yield | -133.9% | -23.3% |
| FCF Yield | -121.9% | -8.72% |
Shares
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Shares Outstanding | 2,959,470 | 58,127,000 |
| Shares Change (YoY) | 95.4% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 2,879,070 | 49,136,700 |
| Shares Held by Insiders | 2.72% | 11.6% |
| Shares Held by Institutions | 24.3% | 59.4% |
Scores
| Measure | Cardio Diagnostics | Industry median |
|---|---|---|
| Altman Z-Score | -1.74 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Cardio Diagnostics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.